| [1] |
CARBONE M, MELLS GF, PELLS G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology, 2013, 144(3): 560-569. e7; quiz e13-14. DOI: 10.1053/j.gastro.2012.12.005. |
| [2] |
ÖRNOLFSSON KT, LUND SH, OLAFSSON S, et al. Biochemical response to ursodeoxycholic acid among PBC patients: A nationwide population-based study[J]. Scand J Gastroenterol, 2019, 54(5): 609-616. DOI: 10.1080/00365521.2019.1606931. |
| [3] |
KUMAGI T, GUINDI M, FISCHER SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105(10): 2186-2194. DOI: 10.1038/ajg.2010.216. |
| [4] |
SAFFIOTI F, GURUSAMY KS, EUSEBI LH, et al. Pharmacological interventions for primary biliary cholangitis: An attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3(3): CD011648. DOI: 10.1002/14651858.CD011648.pub2. |
| [5] |
MARKHAM A, KEAM SJ. Obeticholic acid: First global approval[J]. Drugs, 2016, 76(12): 1221-1226. DOI: 10.1007/s40265-016-0616-x. |
| [6] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. DOI: 10.1016/j.jhep.2017.03.022. |
| [7] |
LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145. |
| [8] |
HIRSCHFIELD GM, DYSON JK, ALEXANDER G, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67(9): 1568-1594. DOI: 10.1136/gutjnl-2017-315259. |
| [9] |
NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840. |
| [10] |
PARÉS A, CABALLERÍA L, RODÉS J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver[J]. J Hepatol, 2000, 32(4): 561-566. DOI: 10.1016/s0168-8278(00)80216-0. |
| [11] |
MUELLER M, THORELL A, CLAUDEL T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity[J]. J Hepatol, 2015, 62(6): 1398-1404. DOI: 10.1016/j.jhep.2014.12.034. |
| [12] |
PELLICCIARI R, FIORUCCI S, CAMAIONI E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity[J]. J Med Chem, 2002, 45(17): 3569-3572. DOI: 10.1021/jm025529g. |
| [13] |
WANG YD, CHEN WD, WANG M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response[J]. Hepatology, 2008, 48(5): 1632-1643. DOI: 10.1002/hep.22519. |
| [14] |
|
| [15] |
GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: Pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7. |
| [16] |
KJÆRGAARD K, FRISCH K, SØRENSEN M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 74(1): 58-65. DOI: 10.1016/j.jhep.2020.07.028. |
| [17] |
SINGH AB, DONG B, KRAEMER FB, et al. Farnesoid X receptor activation by obeticholic acid elevates liver low-density lipoprotein receptor expression by mRNA stabilization and reduces plasma low-density lipoprotein cholesterol in mice[J]. Arterioscler Thromb Vasc Biol, 2018, 38(10): 2448-2459. DOI: 10.1161/ATVBAHA.118.311122. |
| [18] |
HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761. e8. DOI: 10.1053/j.gastro.2014.12.005. |
| [19] |
ZHANG Y, LACERTE C, KANSRA S, et al. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models[J]. Pharmacol Res Perspect, 2017, 5(6): e00368. DOI: 10.1002/prp2.368. |
| [20] |
GHONEM NS, ASSIS DN, BOYER JL. Fibrates and cholestasis[J]. Hepatology, 2015, 62(2): 635-643. DOI: 10.1002/hep.27744. |
| [21] |
KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67(5): 1890-1902. DOI: 10.1002/hep.29569. |
| [22] |
TRAUNER M, NEVENS F, SHIFFMAN ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453. DOI: 10.1016/S2468-1253(19)30094-9. |
| [23] |
CARBONE M, HARMS MH, LAMMERS WJ, et al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis[J]. Hepatol Commun, 2018, 2(6): 683-692. DOI: 10.1002/hep4.1180. |
| [24] |
NEVENS F, MITCHELL S, DRENTH JP, et al. Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis[J]. Digest Liver Dis, 2020, 52: S158.
|
| [25] |
ROBERTS SB, ISMAIL M, KANAGALINGAM G, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis[J]. Hepatol Commun, 2020, 4(9): 1332-1345. DOI: 10.1002/hep4.1518. |
| [26] |
PARÉS A, SHIFFMAN M, VARGAS V, et al. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis[J]. Liver Int, 2020, 40(5): 1121-1129. DOI: 10.1111/liv.14429. |
| [27] |
JUNG HE, JANG JY, JEONG SW, et al. Prognostic indicators in primary biliary cirrhosis: Significance of revised IAHG (International Autoimmune Hepatitis Group) score[J]. Clin Mol Hepatol, 2012, 18(4): 375-382. DOI: 10.3350/cmh.2012.18.4.375. |
| [28] |
LEVITT DG, LEVITT MD. Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease[J]. Clin Exp Gastroenterol, 2014, 7: 307-328. DOI: 10.2147/CEG.S64283. |
| [29] |
YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(1): 48-63. DOI: 10.1038/s41395-018-0390-3. |
| [30] |
BOWLUS CL, POCKROS PJ, KREMER AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2020, 18(5): 1170-1178. e6. DOI: 10.1016/j.cgh.2019.09.050. |
| [31] |
GOMEZ E, GARCIA BUEY L, MOLINA E, et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid[J]. Aliment Pharmacol Ther, 2021, 53(4): 519-530. DOI: 10.1111/apt.16181. |
| [32] |
LI X, LIAO M, PAN Q, et al. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: A systematic review[J]. Eur J Gastroenterol Hepatol, 2020, 32(9): 1116-1122. DOI: 10.1097/MEG.0000000000001785. |
| [33] |
SAMUR S, KLEBANOFF M, BANKEN R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J]. Hepatology, 2017, 65(3): 920-928. DOI: 10.1002/hep.28932. |
| [34] |
D' AMATO D, de VINCENTIS A, MALINVERNO F, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis[J]. JHEP Rep, 2021, 3(2): 100248. DOI: 10.1016/j.jhepr.2021.100248. |
| [35] |
HARMS MH, HIRSCHFIELD GM, FLOREANI A, et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis[J]. JHEP Rep, 2021, 3(1): 100191. DOI: 10.1016/j.jhepr.2020.100191. |
| [36] |
KURIHARA T, NⅡMI A, MAEDA A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid[J]. Am J Gastroenterol, 2000, 95(10): 2990-2992. DOI: 10.1111/j.1572-0241.2000.03220.x. |
| [37] |
REIG A, SESÉ P, PARÉS A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J]. Am J Gastroenterol, 2018, 113(1): 49-55. DOI: 10.1038/ajg.2017.287. |
| [38] |
CORPECHOT C, CHAZOUILLÈRES O, ROUSSEAU A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181. DOI: 10.1056/NEJMoa1714519. |
| [39] |
CHUNG SW, LEE JH, KIM MA, et al. Additional fibrate treatment in UDCA-refractory PBC patients[J]. Liver Int, 2019, 39(9): 1776-1785. DOI: 10.1111/liv.14165. |
| [40] |
HONDA A, TANAKA A, KANEKO T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis[J]. Hepatology, 2019, 70(6): 2035-2046. DOI: 10.1002/hep.30552. |
| [41] |
SMETS L, VERBEEK J, KORF H, et al. Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate[J]. Hepatology, 2021, 73(6): 2598-2600. DOI: 10.1002/hep.31613. |
| [42] |
MURILLO PEREZ CF, HARMS MH, LINDOR KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase[J]. Am J Gastroenterol, 2020, 115(7): 1066-1074. DOI: 10.14309/ajg.0000000000000557. |
| [43] |
SORET PA, LAM L, CARRAT F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2021, 53(10): 1138-1146. DOI: 10.1111/apt.16336. |
| [44] |
REIG A, ÁLVAREZ-NAVASCUÉS C, VERGARA M, et al. Obeticholic acid and fibrates in primary biliary cholangitis: Comparative effects in a multicentric observational study[J]. Am J Gastroenterol, 2021, 116(11): 2250-2257. DOI: 10.14309/ajg.0000000000001343. |
DownLoad: